CENTANY AT (mupirocin)

There are 0 contraindications.

There are 0 severe contraindications.

There are 1 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
No disease contraindications

There are 3 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Anaphylaxis Angioedema Clostridioides difficile infection

There are 15 less severe adverse reactions.

More Frequent	Less Frequent
Headache disorder Nausea Skin rash	Dry skin Erythema Pruritus of skin Skin inflammation Skin swelling Stinging of skin Treatment site sequelae

Rare/Very Rare
Acute abdominal pain Aphthous stomatitis Dizziness Pain Urticaria

Data are insufficient to determine whether there is a drug-associated risk with use of mupirocin ointment for dermatologic use, mupirocin calcium cream for dermatologic use, or mupirocin calcium ointment for intranasal use in pregnant women. One manufacturer states that mupirocin ointment for dermatologic use should be used during pregnancy only if clearly needed. Systemic absorption of mupirocin following topical application to intact skin is minimal.

Although systemic absorption of mupirocin was reported to be negligible following intranasal application of mupirocin calcium ointment for intranasal use in adults, the dosage regimen used in this study did not mimic the recommended intranasal dosage. Reproduction studies in rats or rabbits using subcutaneous mupirocin in dosages up to 22 or 43 times, respectively, the usual human topical dosage or up to 65 or 130 times, respectively, the usual human intranasal dosage have not revealed evidence of developmental toxicity.

It is not known whether systemically absorbed mupirocin is distributed into human milk, affects milk production, or affects the breast-fed infant. Because systemic absorption of mupirocin is minimal following topical application to skin and negligible following intranasal administration, the manufacturers state that mupirocin exposure in breast-feeding infants is unlikely. The benefits of breast-feeding and the importance of mupirocin to the woman should be considered along with potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.

One manufacturer states that mupirocin ointment for dermatologic use should be used with caution in nursing women. If a breast and/or nipple is being treated with mupirocin ointment for dermatologic use or mupirocin calcium cream for dermatologic use, the treated area should be thoroughly washed prior to breast-feeding to minimize oral exposure to the drug in the breast-feeding infant.

No enhanced Geriatric Use information available for this drug.